Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Total Non-Current Liabilities (2021 - 2026)

MoonLake Immunotherapeutics' Total Non-Current Liabilities history spans 6 years, with the latest figure at $100.2 million for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 34.18% to $100.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $100.2 million through Mar 2026, up 34.18% year-over-year, with the annual reading at $74.5 million for FY2025, 3482.2% up from the prior year.
  • Total Non-Current Liabilities came in at $100.2 million for Q1 2026, up from $74.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $100.2 million in Q1 2026 to a low of $4985.0 in Q3 2022.
  • The 5-year median for Total Non-Current Liabilities is $2.6 million (2024), against an average of $25.9 million.
  • Year-over-year, Total Non-Current Liabilities soared 5285.82% in 2023 and then tumbled 32.57% in 2024.
  • MoonLake Immunotherapeutics' Total Non-Current Liabilities stood at $411157.0 in 2022, then skyrocketed by 649.94% to $3.1 million in 2023, then plummeted by 32.57% to $2.1 million in 2024, then soared by 3482.2% to $74.5 million in 2025, then skyrocketed by 34.59% to $100.2 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Total Non-Current Liabilities are $100.2 million (Q1 2026), $74.5 million (Q4 2025), and $74.8 million (Q3 2025).